Lomitapide · Juxtapid
Small molecule
Also known as AEGR-733, BMS-201038
Evidence outlook
Approved: Homozygous Familial Hypercholesterolemia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Weak signal
Also approved (3)
- Homozygous familial hypercholesterolemia
- JUXTAPID® (lomitapide capsules) is indicated as an adjunct to a low-fat diet and other lipid- lowering drugs, with or without LDL apheresis, to reduce low-density lipoprotein cholesterol (LDL-C) in adult patients with homozygous familial hypercholesterolemia (HoFH). Due to its benefit-risk profile, the prescribing of JUXTAPID should be limited to physicians experienced in the diagnosis and treatment of familial hypercholesterolemia. The effect of JUXTAPID on cardiovascular morbidity and mortality has not been determined.
- Homozygous familial hypercholesterolaemia in adults (marketing authorisation holder now Chiesi Farmaceutici)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00730236 NCT00730236 · Homozygous Familial Hypercholesterolemia This was a nonrandomized, open-label, single-group study of 29 participants with no placebo or active comparator. Although the clinical primary endpoint—change in LDL-C—showed a mean reduction of 40.1% at week 26, there was no randomized comparison to establish statistical efficacy. Registry: NCT00730236 | 3 | Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) (Baseline and Week 26) 2010-09 | Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) (Baseline and Week 26): Lomitapide Escalated -40.1% (Standard Deviation 31.25) | Weak signal | link ↗ |
View 2 more trials
NCT04681170 NCT04681170 · Homozygous Familial Hypercholesterolaemia (HoFH) This was an open-label, non-randomized study with no placebo or active comparator: all participants received lomitapide in age-based dosing groups. The primary endpoint, percent change in LDL-C from baseline at Week 24, is a hard clinical lipid endpoint and was met (mean -53.9%, p<0.0001 from a one-sample test), but without a control group the drug effect cannot be separated from background lipid-lowering therapy, diet, or natural course. The uncontrolled design is the key limitation and caps the evidence at weak. Registry: NCT04681170 | 3 | Efficacy Endpoint: Percent Change in Low-density Lipoprotein Cholesterol (LDL C) at Week 24 Compared to Baseline (Baseline through Week 24) 2022-10-16 | Efficacy Endpoint: Percent Change in Low-density Lipoprotein Cholesterol (LDL C) at Week 24 Compared to Baseline (Baseline through Week 24): Age 5-10 Years -56.529% (Standard Deviation 26.5401) | Age 11-17 Years -51.633% (Standard Deviation 25.5658) | Weak signal | link ↗ |
NCT02173158 NCT02173158 · Familial Hypercholesterolemia - Homozygous The study was a single-arm, open-label trial of 9 participants receiving lomitapide alongside existing lipid-lowering therapy, with no placebo or active comparator and no formal between-group primary endpoint comparison. Its primary endpoint was the clinical disease-defining lipid measure LDL-C, but the uncontrolled design limits the strength of the evidence despite the reported mean reduction. Registry: NCT02173158 | 3 | Percent Change in LDL-C (Baseline to Week 26) 2015-04-03 | Percent Change in LDL-C (Baseline to Week 26): Lomitapide -42.2% (Standard Deviation 18.16) | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Homozygous Familial Hypercholesterolemia: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Lomitapide (Juxtapid): this drug | Approved | Small molecule | MTP | Weak signal | NCT04681170: Efficacy Endpoint: Percent Change in Low-density Lipoprotein Cholesterol (LDL C) at Week 24 Compared to Baseline (Baseline through Week 24): Age 5-10 Years -56.529% (Standard Deviation 26.5401) | Age 11-17 Years -51.633% (Standard Deviation 25.5658) NCT02173158: Percent Change in LDL-C (Baseline to Week 26): Lomitapide -42.2% (Standard Deviation 18.16) | |
| Alirocumab (Praluent) | Approved | Monoclonal antibody | PCSK9 | Partial signal | NCT03156621: Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12 (Intent-to-Treat [ITT] Estimand) (Baseline to Week 12): Alirocumab 150 mg SC Q2W -26.9 Percentage of change (Standard Error 4.6) vs Placebo in DBTP 8.6 Percentage of change (Standard Error 6.3) | |
| Evinacumab (Evkeeza) | Approved | Monoclonal antibody | ANGPTL3 | Partial signal | NCT03399786: Percent Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 24 (Intent-to-Treat [ITT] Estimand) (Week 24): Evinacumab 15 mg/kg IV Q4W -47.1% (Standard Error 4.6) vs Placebo IV Q4W 1.9% (Standard Error 6.5) | |
| Evolocumab (Repatha) | Approved | Monoclonal antibody | PCSK9 | Reliable signal | NCT01588496: Part B: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12: Evolocumab -23.05% (Standard Error 3.78) vs Placebo 7.88% (Standard Error 5.26); LS mean treatment difference -30.93% (95% CI -43.86 to -18.00), p<0.001 | |
| Ezetimibe (Zetia) | Approved | Small molecule | Dietary Cholesterol Absorption Inhibitor, NPC1L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Ezetimibe / Simvastatin (Vytorin) | Approved | Small molecule | HMG-CoA reductase / NPC1L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Inclisiran (Leqvio) | Approved | RNA / oligonucleotide | PCSK9 | Partial signal | NCT04659863: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -21.6% (Standard Deviation 13.36) vs Part 1 - Placebo 11.7% (Standard Deviation 30.52) | |
| Rosuvastatin | Approved | Small molecule | HMG-CoA reductase | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-1918 | Phase 3 | Monoclonal antibody | ANGPTL3 | Partial signal | NCT06723652: LDL-C -58.8% vs +5.5% with placebo at week 12 (difference -64.2%), ESC 2026 | |
| Zodasiran | Phase 3 | RNA / oligonucleotide | ANGPTL3 gene mRNA (hepatic) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent